Event Summary Is America’s cancer care structure in crisis? On Friday, AEI’s Scott Gottlieb teamed up with the National Coalition for Cancer Survivorship to host a half-day symposium promoting cancer care reform. Representative Tom Price focused on big-picture requirements for effective care, citing flexibility and innovation as essential to positive change. While advancements in medical technology and practice show increasingly significant potential, Rep.Price argued that these aids cannot be harnessed under a system in which autonomy is not ceded to both providers and patients. The patient-provider discussion continued in the two subsequent panels. In the first panel, Dr. Michael Kolodziej weighed in on the limits of the Affordable Care Act in prompting reform in oncology, and Dr. John Sprandio stressed physician-led care backed by process standardization. Dr. Peter Ubel clarified the distinction between insurance and insulation, pointing out that protecting against catastrophic risk is cost-intensive. In the second panel, Lillian Schockeny of the Johns Hopkins Breast Center aptly summed up the discussion with the quip, “We need to know our patients way beyond their pathology.” Shelly Fuld Nasso of the National Coalition for Cancer Survivorship agreed, saying that standard process in treatment does not take the place of communication with patients. Dr. Joshua Sharfstein closed the symposium by echoing Rep. Price’s call for spending on innovation. Dr. Sharfstein stressed the need for a reorientation of the US payment system to aid, not fight against, incentives for patient-provider communication. Event Description In 2013, the Institute of Medicine revisited its groundbreaking 1999 study on the quality of cancer care, ultimately labeling the present care structure “a system in crisis.” Reform is essential to improving the quality of care — namely, to ensuring that the system is responsive to the complex needs of aging cancer patients and to guaranteeing that Medicare can be sustained for future generations of cancer patients. During this half-day symposium, panelists will consider the opinions of policymakers, health care providers, patients, and other stakeholders in determining how new payment systems can foster patient-centered cancer care, and how informed and empowered patients can be an active part of the resulting payment models. If you are unable to attend, we welcome you to watch the event live on this page. Full video will be posted within 24 hours.
Registration and Breakfast
Mark McClellan, Brookings Institution
Tom Price, US House of Representatives (R-GA)
Panel I: Models of payment reform that foster patient-centered care
Michael Kolodziej, MD, Aetna
John Sprandio, MD, Consultants in Medical Oncology and Hematology
Peter Ubel, MD, Duke Sanford School of Public Policy
Scott Gottlieb, MD, AEI
Panel II: The optimal patient role in future delivery systems
John Cox, MD, Texas Oncology
Stephanie Dyson, Genentech
Lillian Shockney, Johns Hopkins University
Shelley Fuld Nasso, National Coalition for Cancer Survivorship
Joshua M. Sharfstein, Maryland Department of Health and Mental Hygiene
Event Contact Information
For more information, please contact Kelly Funderburk at [email protected], 202.862.5920.
Media Contact Information
For media inquiries, please contact [email protected], 202.862.5829.
John Cox, MD, is board certified and specializes in internal medicine, medical oncology, and hematology. He serves on the medical staff of Methodist Hospitals of Dallas, where he is past president of the medical staff. Dr. Cox also serves as editor-in-chief of the Journal of Oncology Practice, and is active in both the Texas Society of Clinical Oncology and the American Society of Clinical Oncology.
Stephanie Dyson is the senior director of public policy and reimbursement and government affairs for Genentech, where she leads and oversees a team that effectively implements public-payer strategies that align with Genentech business objectives. Dyson has extensive policy and regulatory experience and understands the US federal executive and legislative government systems and how they impact health care policy. She also has a deep understanding and knowledge of public-payer emerging trends that can impact access for Genentech’s products and pipeline. Dyson has held multiple senior leadership positions at the Centers for Medicare & Medicaid Services. In these positions she provided executive leadership in the operation and administration of key national programmatic issues. She is a registered nurse by background.
Shelley Fuld Nasso is chief executive officer of the National Coalition for Cancer Survivorship (NCCS). Before joining NCCS, she served in leadership roles at Susan G. Komen where she leveraged the strength of Komen’s grassroots network to strengthen the organization’s reputation and visibility in Washington, DC, and in state capitals. She has also served as director of community philanthropy at The Dallas Foundation and held management positions at communications and technology enterprises.
Scott Gottlieb, MD, is a practicing physician and resident fellow at AEI. From 2005 to 2007, Dr. Gottlieb served as US Food and Drug Administration (FDA) deputy commissioner for medical and scientific affairs. From 2003 to 2004, he served as a senior adviser to the FDA commissioner and as the FDA’s director of medical policy development. He left the FDA in spring 2004 to work on the implementation of the new Medicare prescription drug benefit as a senior adviser to the administrator of the Centers for Medicare and Medicaid Services. Dr. Gottlieb is an editorial board member of the journal Value Based Cancer Care, the Food and Drug Law Institute’s Policy Forum, and is a member of the board of advisers of Cancer Commons. He writes a regular column for The Wall Street Journal. Dr. Gottlieb is also a member of the policy boards for both the Society of Hospitalist Medicine and the Leukemia and Lymphoma Society and serves as a director to public and private life science and health care services companies. He is likewise a clinical assistant professor at the New York University School of Medicine.
Michael Kolodziej, MD, is the national medical director for oncology solutions in the office of the chief medical officer at Aetna. Dr. Kolodziej served as an associate professor at the University of Oklahoma College of Medicine in the beginning of his career, and then joined New York Oncology in the winter of 1998, where he was a partner until December 2012. Previously an active member of the US Oncology (USON) pharmacy and therapeutics committee, he served on the executive committee from 2002 to 2011 and as chairman from 2004 to 2011. Additionally, he was medical director of oncology services for US Oncology from 2007 to 2011, where he helped direct the implementation of the USON clinical pathways initiative, the integration of USON electronic medical records into this program, and the development of the USON disease management and advanced-care planning programs, now known as Innovent Oncology. He has published several manuscripts and given several presentations on the cost of cancer care, oncology reimbursement reform, and the use of evidence based treatment to enhance value. He is a fellow of the American College of Physicians and is a member of the board of the Personalized Medicine Coalition.
Mark McClellan is a senior fellow and director of the Health Care Innovation and Value Initiative at the Brookings Institution. Within Brookings, his work focuses on promoting quality and value in patient-centered health care. A doctor and economist by training, he also has a highly distinguished record in public service and academic research. Dr. McClellan is a former administrator of the Centers for Medicare & Medicaid Services and former commissioner of the US Food and Drug Administration (FDA) where he developed and implemented major reforms in health policy. These include the Medicare prescription drug benefit, the FDA’s Critical Path Initiative, and public-private initiatives to develop better information on the quality and cost of care. Dr. McClellan chairs the FDA’s Reagan-Udall Foundation, is cochair of the Quality Alliance Steering Committee, sits on the National Quality Forum’s board of directors, is a member of the Institute of Medicine, and is a research associate at the National Bureau of Economic Research. He previously served as a member of the President’s Council of Economic Advisers and senior director for health care policy at the White House, and was an associate professor of economics and medicine at Stanford University.
Tom Price was first elected to represent Georgia’s Sixth Congressional District in November 2004. Before that, Rep. Price served four terms in the Georgia State Senate, including two as minority whip. In 2002, he was a leader in the Republican renaissance in Georgia as the party took control of the State Senate, with Rep. Price rising to become the first Republican Senate majority leader in the history of Georgia. In Congress, he serves on the House Committee on Ways & Means and the House Committee on Education and the Workforce. In the 113th Congress, Rep. Price was named vice chairman of the House Committee on the Budget. In previous Congresses, he has served as chairman of the House Republican Policy Committee and chairman of the Republican Study Committee. Committed to advancing positive solutions under principled leadership, Rep. Price has been a fierce opponent of government waste and devoted to limited government and lower spending. For nearly 20 years, he worked in private practice as an orthopedic surgeon. Before coming to Washington, DC, he returned to Emory University School of Medicine as an assistant professor and medical director of the Orthopedic Clinic at Grady Memorial Hospital in Atlanta, teaching resident doctors in training.
Joshua M. Sharfstein, MD, serves as secretary of the Maryland Department of Health and Mental Hygiene. Before his post with the State of Maryland, he served as the principal deputy commissioner of the US Food and Drug Administration, the agency’s second-highest-ranking position. He was appointed by President Obama in March 2009, serving first as acting commissioner through May 2009 and then as principal deputy commissioner through January 2011. From December 2005 through March 2009, Dr. Sharfstein served as the commissioner of health for the City of Baltimore. In this position, he led the efforts to expand literacy in pediatric primary care, facilitate the transition to Medicare Part D for disabled adults, engage college students in public health activities, increase influenza vaccination of health care workers, and expand access to effective treatment for opioid addiction. Under his leadership, the Baltimore Health Department and its affiliated agencies won multiple national awards for innovative programs. In 2008, Dr. Sharfstein was named Public Official of the Year by Governing Magazine. From July 2001 to December 2005, he served as minority professional staff of the Government Reform Committee of the US House of Representatives for Congressman Henry A. Waxman (D-CA).
Lillian Shockney has been the administrative director of the Johns Hopkins Breast Center since 1997. A two-time breast cancer survivor and registered nurse, Shockney has worked to improve the care of breast cancer patients around the world. She has worked at Johns Hopkins since 1983, where she is responsible for the quality of care programs; patient education programs; the survivor volunteer team; community outreach at a local, regional, and national level; and the website and patient advocacy. In November 2011, she also became the director of the Johns Hopkins Cancer Survivorship programs. A published author and nationally recognized public speaker, she has written 13 books and more than 250 articles on the subject of breast cancer. She is also editor-in-chief of the Journal of Oncology Navigation and Survivorship. She is the founder and program director of the Academy of Oncology Nurse Navigators. In 2008, the Johns Hopkins Board of Trustees appointed Shockney to a chair as a University Distinguished Service Assistant Professor of Breast Cancer, the first time in the history of the institution that a hospital nurse has been appointed to a distinguished-service designation. She is now an associate professor in the School of Medicine and has received 37 national and 4 state awards.
John Sprandio, MD, is chief of medical oncology and hematology at Delaware County Memorial Hospital, director of the Delaware County Regional Cancer Center, and a member of the Fox Chase Network. Board certified in internal medicine, medical oncology, and hematology, he is the lead physician of Consultants in Medical Oncology & Hematology, a single-specialty practice. He is a fellow of the American College of Physicians and a member of the American Society of Clinical Oncology and the American Society of Hematology. His contribution to “Making a Business Case for Quality” (American Heart Hospital Journal, 2006) led to his oncology practice becoming the first specialty practice to be recognized by the National Committee for Quality Assurance as a Level III Patient-Centered Medical Home. He is the founder and managing partner of Oncology Management Services Inc. (OMS), a consulting firm providing transformation-related services. Dr. Sprandio also serves on a Centers for Medicare & Medicaid Services Oncology Payment Reform Technical Expert Panel convened by MITRE and the Brookings Institution and on a cancer bundling consortium, a broad group of stakeholders convened by the Center for American Progress and spearheaded by Ezekiel Emanuel. Dr. Sprandio has spoken widely regarding the Oncology Patient Centered Medical Home model and is dedicated to continuously improving the quality and value of cancer care.
Peter Ubel, MD, is a physician and behavioral scientist whose research and writing explores the quirks in human nature that influence people’s lives — the mixture of rational and irrational forces that affect health, happiness, and the way society functions. Dr. Ubel currently works at Duke University as a Jack O. Blackburn Professor of Marketing in the Fuqua School of Business and as a professor of public policy in the Sanford School of Public Policy where he specializes in health policy and economics. He was a professor of medicine and psychology at the University of Michigan from 2000 to 2010 and later went on to direct the Center for Behavioral and Decision Sciences in Medicine. His research explores controversial issues about the role of values and preferences in health care decision making. He uses the tools of decision psychology and behavioral economics to explore topics such as informed consent, shared decision making, and health care rationing.